{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"TriSalus Life Sciences, Inc."},"Symbol":{"label":"Symbol","value":"TLSIW"},"Address":{"label":"Address","value":"6272 W, WESTMINSTER, 80031, United States"},"Phone":{"label":"Phone","value":""},"Industry":{"label":"Industry","value":"Medical Specialities"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"TriSalus Life Sciences was created to develop and commercialize an innovative approach for the treatment of liver and pancreatic tumors. Our platform approach addresses immune dysfunction in liver and pancreatic tumors by combining immunotherapy drugs with highly effective drug delivery technology. Our companyâs heritage is in the development of devices for our Pressure-Enabled Drug Deliveryâ\"¢ (PEDDâ\"¢) method. Building on this history, we launched our new platform in 2020 with the acquisition of SD-101. SD-101 is an investigational toll-like receptor 9 (TLR9) agonist with the potential to modulate the immune system to enable immunotherapy."},"CompanyUrl":{"label":"Company Url","value":"https://www.trisaluslifesci.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Bryan F. Cox","title":"Chief Scientific & Manufacturing Officer"},{"name":"Mary T. Szela","title":"President, Chief Executive Officer & Director"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}